Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Οι συνταγές μου Αποθηκεύστε τις συνταγές σας και μοιραστείτε τις εύκολα και με ασφάλεια
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

Rapifen 500 micrograms/ml solution for injection or infusion (2012)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης Janssen-Cilag Ltd
Διεύθυνση 50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Name of the medicinal product

Rapifen.

Qualitative and quantitative composition

Each ml of Rapifen contains alfentanil hydrochloride 544 micrograms, equivalent to 500 micrograms alfentanil base.

Pharmaceutical form

Aqueous injection.

Therapeutic indications

As an analgesic supplement for use before and during anaesthesia. It is indicated for: Short procedures and outpatient surgery. Procedures of medium and long duration when given as a bolus followed by ...

Posology and method of administration

For intravenous administration. Rapifen by the intravenous route can be administered to both adults and children. The dosage of Rapifen should be individualised according to age, bodyweight, physical status, ...

Contraindications

Obstructive airways disease or respiratory depression if not ventilating. Concurrent administration with monoamine oxidase inhibitors or within 2 weeks of their discontinuation. Administration in labour ...

Special warnings and precautions for use

Warnings Following administration of Rapifen, a fall in blood pressure may occur. The magnitude of this effect may be exaggerated in the hypovolaemic patient or in the presence of concomitant sedative ...

Interaction with other medicinal products and other forms of interaction

Potential for Rapifen to affect other medicinal products In combination with alfentanil, the blood concentrations of propofol are 17% higher than in the absence of alfentanil. The concomitant use of alfentanil ...

Pregnancy and lactation

Although no teratogenic or acute embryotoxic effects have been observed in animal experiments, insufficient data are available to evaluate any harmful effects in man. Consequently, it is necessary to consider ...

Effects on ability to drive and use machines

Where early discharge is envisaged, patients should be advised not to drive or operate machinery for the 24 hours following administration.

Undesirable effects

Adverse Drug Reactions The most frequently reported ADRs (incidence ≥10%) are: nausea and vomiting. Undesirable effects listed below in Table 1 have been reported in clinical trials (1157 subjects) and/or ...

Overdose

The manifestations of alfentanil overdose are generally an extension of its pharmacological action, which include the following: Action Bradycardia Anticholinergics such as atropine or glycopyrrolate. ...

Pharmacodynamic properties

The analgesic potency of Rapifen is one quarter that of fentanyl. The duration of action of Rapifen is one third that on an equianalgesic dose of fentanyl and is clearly dose-related. Its depressant effects ...

Pharmacokinetic properties

Alfentanil is a synthetic opioid with µ-agonist pharmacological effects. After bolus injections ranging from 2.4 to 125 µg/kg, plasma levels in man decay triexponentially with a terminal half life of approximately ...

Preclinical safety data

Preclinical effects observed were only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.

List of excipients

Sodium chloride Water for injection

Incompatibilities

See Dosage and dosage schedules.

Shelf life

5 years.

Special precautions for storage

Store in a controlled drug store. This medicinal product does not require any special storage conditions.

Nature and contents of container

Colourless glass one-point-cut ampoules (PhEur, Type I). Pack size: packs of 10 2 ml ampoules; packs of 5 and 10 10 ml ampoules.

Special precautions for disposal and other handling

For single use only. Discard any unused contents.

Marketing authorization holder

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG UK

Marketing authorization number(s)

PL 0242/0091

Date of first authorization / renewal of the authorization

27 July 1983/30 March 2004

Date of revision of the text

11 July 2012
Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.